<!DOCTYPE html><html><head><title>Schizophrenia: percent of patients with severe symptoms or side effects and no recent medication treatment change to address these problems.</title><link rel="stylesheet" type="text/css" href="style.css"></head><body><div class='section'>
<h2>General
</h2>
<div class='field field_text'>
<h3>
Title
</h3>
<div class='FieldValue'>
<div class="content_title">Schizophrenia: percent of patients with severe symptoms or side effects and no recent medication treatment change to address these problems.</div>
</div>

</div>
<div class='field field_citation'>
<h3>
Source(s)
</h3>
<div class='FieldValue'>
<table><tr><td>Young AS, Sullivan G, Burnam MA, Brook RH. Measuring the quality of outpatient treatment for schizophrenia. Arch Gen Psychiatry. 1998 Jul;55(7):611-7. <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=9672051" target="_blank">PubMed</a></td></tr></table>
</div>

</div>

</div>
<div class='section'>
<h2>Measure Domain
</h2>
<div class='field field_picklist-one'>
<h3>
Primary Measure Domain
</h3>
<div class='FieldValue'>
Process<div class="content_special_handling"><p>The validity of measures depends on how they are built. By examining the key building blocks of a measure, you can assess its validity for your purpose. For more information, visit the <a href="/selecting-and-using/validity.aspx">Measure Validity</a> page.<p/></div>
</div>

</div>
<div class='field field_picklist-many'>
<h3>
Secondary Measure Domain
</h3>
<div class='FieldValue'>
Does not apply to this measure
</div>

</div>

</div>
<div class='section'>
<h2>Brief Abstract
</h2>
<div class='field field_text'>
<h3>
Description
</h3>
<div class='FieldValue'>
<div class="content_para"><p>This measure is used to assess the percent of patients who have severe symptoms or side effects and no change in medication treatment change to address these problems.</p></div>
</div>

</div>
<div class='field field_text'>
<h3>
Rationale
</h3>
<div class='FieldValue'>
<div class="content_para"><p>Schizophrenia is a chronic, disabling brain disorder that occurs in about 1% of the population.  It accounts for more than 10% of all disabled people in the United States (U.S.) and 2.5% of all U.S. healthcare expenditures.  The cost due to society of schizophrenia is enormous (more than $20 billion/year in the U.S. alone).  The quality of care for schizophrenia is frequently poor.  There is a critical need for measures of important domains of treatment process for this disorder.</p>

<p>Appropriate medication management reduces symptoms, relapse and rehospitalization and can improve functioning and quality of life.</p></div>
</div>

</div>
<div class='field field_text'>
<h3>
Primary Clinical Component
</h3>
<div class='FieldValue'>
<div class="content_para"><p>Schizophrenia; psychotic symptoms; antipsychotic medication side effects (akathisia, parkinsonism, tardive dyskinesia); medication management</p></div>
</div>

</div>
<div class='field field_text'>
<h3>
Denominator Description
</h3>
<div class='FieldValue'>
<div class="content_para"><p>The number of patients with schizophrenia in the sample (see the related "Denominator Inclusions/Exclusions" field)</p></div>
</div>

</div>
<div class='field field_text'>
<h3>
Numerator Description
</h3>
<div class='FieldValue'>
<div class="content_para"><p>The number of patients in the denominator with severe symptoms or side effects and no recent medication treatment change to address these problems (see the related "Numerator Inclusions/Exclusions" field in ththe Complete Summary).</p></div>
</div>

</div>

</div>
<div class='section'>
<h2>Evidence Supporting the Measure
</h2>
<div class='field field_picklist-choice'>
<h3>
Evidence Supporting the Criterion of Quality
</h3>
<div class='FieldValue'>
A clinical practice guideline or other peer-reviewed synthesis of the clinical evidence
</div>
<div class='FieldValue'>
A formal consensus procedure involving experts in relevant clinical, methodological, and organizational sciences
</div>
<div class='FieldValue'>
A systematic review of the clinical literature
</div>
<div class='FieldValue'>
One or more research studies published in a National Library of Medicine (NLM) indexed, peer-reviewed journal
</div>

</div>

</div>
<div class='section'>
<h2>Evidence Supporting Need for the Measure
</h2>
<div class='field field_picklist-choice'>
<h3>
Need for the Measure
</h3>
<div class='FieldValue'>
Overall poor quality for the performance measured
</div>
<div class='FieldValue'>
Variation in quality for the performance measured
</div>

</div>
<div class='field field_citation'>
<h3>
Evidence Supporting Need for the Measure
</h3>
<div class='FieldValue'>
<table><tr><td>Lehman AF, Steinwachs DM. Patterns of usual care for schizophrenia: initial results from the Schizophrenia Patient Outcomes Research Team (PORT) Client Survey. Schizophr Bull. 1998;24(1):11-20; discussion 20-32. <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=9502543" target="_blank">PubMed</a></td></tr></table>
</div>
<div class='FieldValue'>
<table><tr><td>Lehman AF. Quality of care in mental health: the case of schizophrenia. Health Aff (Millwood). 1999 Sep-Oct;18(5):52-65. <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=10495592" target="_blank">PubMed</a></td></tr></table>
</div>
<div class='FieldValue'>
<table><tr><td>Young AS, Sullivan G, Burnam MA, Brook RH. Measuring the quality of outpatient treatment for schizophrenia. Arch Gen Psychiatry. 1998 Jul;55(7):611-7. <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=9672051" target="_blank">PubMed</a></td></tr></table>
</div>

</div>

</div>
<div class='section'>
<h2>State of Use of the Measure
</h2>
<div class='field field_picklist-one'>
<h3>
State of Use
</h3>
<div class='FieldValue'>
Current routine use
</div>

</div>
<div class='field field_picklist-choice'>
<h3>
Current Use
</h3>
<div class='FieldValue'>
Internal quality improvement
</div>

</div>

</div>
<div class='section'>
<h2>Application of Measure in its Current Use
</h2>
<div class='field field_picklist-choice'>
<h3>
Care Setting
</h3>
<div class='FieldValue'>
Ambulatory Care
</div>
<div class='FieldValue'>
Behavioral Health Care
</div>

</div>
<div class='field field_picklist-choice'>
<h3>
Professionals Responsible for Health Care
</h3>
<div class='FieldValue'>
Physicians
</div>

</div>
<div class='field field_picklist-one'>
<h3>
Lowest Level of Health Care Delivery Addressed
</h3>
<div class='FieldValue'>
Single Health Care Delivery Organizations
</div>

</div>
<div class='field field_text'>
<h3>
Target Population Age
</h3>
<div class='FieldValue'>
<div class="content_para"><p>Age greater than or equal to 18 years</p></div>
</div>

</div>
<div class='field field_picklist-one'>
<h3>
Target Population Gender
</h3>
<div class='FieldValue'>
Either male or female
</div>

</div>
<div class='field field_text'>
<h3>
Stratification by Vulnerable Populations
</h3>
<div class='FieldValue'>
<div class="content_para"><p>Unspecified</p></div>
</div>

</div>

</div>
<div class='section'>
<h2>Characteristics of the Primary Clinical Component
</h2>
<div class='field field_text'>
<h3>
Incidence/Prevalence
</h3>
<div class='FieldValue'>
<div class="content_para"><p>Schizophrenia occurs in about 1% of the population.</p></div>
</div>

</div>
<div class='field field_citation'>
<h3>
Evidence for Incidence/Prevalence
</h3>
<div class='FieldValue'>
<table><tr><td>Young AS. Personal communication: NQMC submission form. 2002 Dec 27. &nbsp;3  p. </td></tr></table>
</div>

</div>
<div class='field field_text'>
<h3>
Association with Vulnerable Populations
</h3>
<div class='FieldValue'>
<div class="content_para"><p>Unspecified</p></div>
</div>

</div>
<div class='field field_text'>
<h3>
Burden of Illness
</h3>
<div class='FieldValue'>
<div class="content_para"><p>Schizophrenia is a chronic, disabling brain disorder that accounts for more than 10% of all disabled people in the United States (U.S.).</p></div>
</div>

</div>
<div class='field field_citation'>
<h3>
Evidence for Burden of Illness
</h3>
<div class='FieldValue'>
<table><tr><td>Young AS. Personal communication: NQMC submission form. 2002 Dec 27. &nbsp;3  p. </td></tr></table>
</div>

</div>
<div class='field field_text'>
<h3>
Utilization
</h3>
<div class='FieldValue'>
<div class="content_para"><p>Unspecified</p></div>
</div>

</div>
<div class='field field_text'>
<h3>
Costs
</h3>
<div class='FieldValue'>
<div class="content_para"><p>Schizophrenia accounts for 2.5% of all United States (U.S.) healthcare expenditures.  The cost due to society of schizophrenia is enormous (more than $20 billion/year in the U.S. alone).</p> </div>
</div>

</div>
<div class='field field_citation'>
<h3>
Evidence for Costs
</h3>
<div class='FieldValue'>
<table><tr><td>Young AS. Personal communication: NQMC submission form. 2002 Dec 27. &nbsp;3  p. </td></tr></table>
</div>

</div>

</div>
<div class='section'>
<h2>Institute of Medicine (IOM) Healthcare Quality Report Categories
</h2>
<div class='field field_picklist-choice'>
<h3>
IOM Care Need
</h3>
<div class='FieldValue'>
Living with Illness
</div>

</div>
<div class='field field_picklist-choice'>
<h3>
IOM Domain
</h3>
<div class='FieldValue'>
Effectiveness
</div>

</div>

</div>
<div class='section'>
<h2>Data Collection for the Measure
</h2>
<div class='field field_picklist-one'>
<h3>
Case Finding
</h3>
<div class='FieldValue'>
Users of care only
</div>

</div>
<div class='field field_text'>
<h3>
Description of Case Finding
</h3>
<div class='FieldValue'>
<div class="content_para"><p>Adult patients greater than or equal to 18 years with the diagnosis of schizophrenia or schizoaffective disorder who had been in treatment for at least 3 months</p></div>
</div>

</div>
<div class='field field_text'>
<h3>
Denominator Inclusions/Exclusions
</h3>
<div class='FieldValue'>
<div class="content_para"><p><strong>Inclusions</strong><br>
Eligible patients include adults greater than or equal to 18 years with the diagnosis of schizophrenia or schizoaffective disorder who had been in treatment for at least 3 months and who had at least 1 visit with a psychiatrist during the previous 3 months</p>

<p><strong>Exclusions</strong><br>
Patients with more than 21 days in the hospital during the previous 3 months</p>
                                   

                                    

                     



                         

                                   </div>
</div>

</div>
<div class='field field_picklist-one'>
<h3>
Relationship of Denominator to Numerator
</h3>
<div class='FieldValue'>
All cases in the denominator are equally eligible to appear in the numerator
</div>

</div>
<div class='field field_picklist-choice'>
<h3>
Denominator (Index) Event
</h3>
<div class='FieldValue'>
Clinical Condition
</div>
<div class='FieldValue'>
Diagnostic Evaluation
</div>

</div>
<div class='field field_picklist-one'>
<h3>
Denominator Time Window
</h3>
<div class='FieldValue'>
Time window precedes index event 
</div>

</div>
<div class='field field_text'>
<h3>
Numerator Inclusions/Exclusions
</h3>
<div class='FieldValue'>
<div class="content_para"><p><strong>Inclusions</strong><br />
Poor-quality medication management is defined as either poor-quality symptom management* or poor-quality side effects management.**</p>

<ul class="NoBullets">
<li>*<em>Poor-quality symptom management</em>:<br />
Patients with significant psychotic symptoms<sup>+</sup> and no change in antipsychotic medication dosage or a switch to a different antipsychotic medication within 3 months, and not been offered treatment with clozapine (a medication with greater efficacy)  

<p class="Note"><sup>+</sup>Patients are defined as having significant psychotic symptoms if Brief Psychiatric Rating Scale ratings are "severe" or greater for hallucinations or suspiciousness, or "moderately severe" or greater for unusual thought content or conceptual disorganization.</p>
</li>
<li>**<em>Poor-quality side effects management</em>:<br />
Patients with significant akathisia<sup>++</sup> or parkinsonism<sup>++</sup> and no reduction in the dose of antipsychotic medication, switch to a different antipsychotic medication, or change in anti-side-effect medication within 1 month, and not been offered treatment with clozapine or risperidone (medications with fewer side effects)</li> 
<li>Patients with significant tardive dyskinesia (TD)<sup>++</sup> and no reduction in the dose of antipsychotic medication within 3 months, and not been offered treatment with clozapine (a medication that causes no TD)   

<p class="Note"><sup>++</sup>Patients are defined as having significant akathisia if they meet Barnes criteria for moderate, marked, or severe akathisia; significant parkinsonism if they respond "a great deal" to items regarding muscle stiffness or slowing of movements; and significant tardive dyskinesia if their Abnormal Involuntary Movement Scale ratings meet criteria described by Schooler and Kane (Schooler NR, Kane JM. Research diagnoses for tardive dyskinesia. Arch Gen Psychiatry 1982 Apr;39[4]:486-7).</p>                         </li></ul>

<p><strong>Exclusions</strong><br />
Unspecified</p></div>
</div>

</div>
<div class='field field_picklist-one'>
<h3>
Measure Results Under Control of Health Care Professionals, Organizations and/or Policymakers
</h3>
<div class='FieldValue'>
The measure results are somewhat or substantially under the control of the health care professionals, organizations and/or policymakers to whom the measure applies.
</div>

</div>
<div class='field field_picklist-one'>
<h3>
Numerator Time Window
</h3>
<div class='FieldValue'>
Fixed time period
</div>

</div>
<div class='field field_picklist-choice'>
<h3>
Data Source
</h3>
<div class='FieldValue'>
Medical record
</div>
<div class='FieldValue'>
Patient survey
</div>
<div class='FieldValue'>
Pharmacy data
</div>

</div>
<div class='field field_picklist-one'>
<h3>
Level of Determination of Quality
</h3>
<div class='FieldValue'>
Individual Case
</div>

</div>
<div class='field field_text'>
<h3>
Pre-existing Instrument Used
</h3>
<div class='FieldValue'>
<ul>
<li>Structured Clinical Interview for the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV), Patient Edition
<li>Brief Psychiatric Rating Scale 
<li>Barnes scale 
<li>Liverpool University Neuroleptic Side Effect Rating Scale 
<li>Abnormal Involuntary Movement Scale</li></ul>                         

                   
</div>

</div>

</div>
<div class='section'>
<h2>Computation of the Measure
</h2>
<div class='field field_picklist-one'>
<h3>
Scoring
</h3>
<div class='FieldValue'>
Rate
</div>

</div>
<div class='field field_picklist-one'>
<h3>
Interpretation of Score
</h3>
<div class='FieldValue'>
Better quality is associated with a lower score
</div>

</div>
<div class='field field_picklist-choice'>
<h3>
Allowance for Patient Factors
</h3>
<div class='FieldValue'>
Unspecified
</div>

</div>
<div class='field field_picklist-choice'>
<h3>
Standard of Comparison
</h3>
<div class='FieldValue'>
Internal time comparison
</div>

</div>

</div>
<div class='section'>
<h2>Evaluation of Measure Properties
</h2>
<div class='field field_text'>
<h3>
Extent of Measure Testing
</h3>
<div class='FieldValue'>
<div class="content_para"><p>The measure has been pilot tested in 2 institutions for more than 1 year.</p></div>
</div>

</div>
<div class='field field_citation'>
<h3>
Evidence for Reliability/Validity Testing
</h3>
<div class='FieldValue'>
<table><tr><td>Young AS, Sullivan G, Burnam MA, Brook RH. Measuring the quality of outpatient treatment for schizophrenia. Arch Gen Psychiatry. 1998 Jul;55(7):611-7. <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=9672051" target="_blank">PubMed</a></td></tr></table>
</div>

</div>

</div>
<div class='section'>
<h2>Identifying Information
</h2>
<div class='field field_text'>
<h3>
Original Title
</h3>
<div class='FieldValue'>
<div class="content_para"><p>Poor Quality Medication Treatment: the appropriateness of medication management.</p></div>
</div>

</div>
<div class='field field_text'>
<h3>
Measure Collection Name
</h3>
<div class='FieldValue'>
Method for Assessing Quality in Schizophrenia (MAQS)
</div>

</div>
<div class='field field_orglist'>
<h3>
Submitter
</h3>
<div class='FieldValue'>
Young, Alexander S., MD, MSHS; Veterans Administration Desert Pacific Mental Illness Research, Education and Clinical Center (MIRECC); and University of California Los Angeles - None
</div>

</div>
<div class='field field_orglist-p'>
<h3>
Developer
</h3>
<div class='FieldValue'>
Young, Alexander S., MD, MSHS; Veterans Administration Desert Pacific Mental Illness Research, Education and Clinical Center (MIRECC); and University of California Los Angeles - None
</div>

</div>
<div class='field field_text'>
<h3>
Funding Source(s)
</h3>
<div class='FieldValue'>
<div class="content_para"><p>Support was provided for this work by the Department of Veterans Affairs, by the Robert Wood Johnson Foundation Clinical Scholars Program, by a National Alliance for Research on Schizophrenia and Depression Young Investigator Award, and by the National Institute of Mental Health University of California, Los Angeles Research Center on Managed Care for Psychiatric Disorders.</p></div>
</div>

</div>
<div class='field field_text'>
<h3>
Composition of the Group that Developed the Measure
</h3>
<div class='FieldValue'>
<div class="content_para"><p>Alexander S. Young, MD, MSHS, UCLA, Los Angeles California, and the Department of Veterans Affairs, Los Angeles, California; Greer Sullivan, MD, MSPH, Department of Veterans Affairs, Little Rock, Arkansas, and the University of Arkansas for Medical Science, Little Rock, Arkansas; M. Audrey Burnam, PhD, The RAND Corporation, Santa Monica, California</p>
</div>
</div>

</div>
<div class='field field_text'>
<h3>
Financial Disclosures/Other Potential Conflicts of Interest
</h3>
<div class='FieldValue'>
<div class="content_para"><p>None</p></div>
</div>

</div>
<div class='field field_text'>
<h3>
Adaptation
</h3>
<div class='FieldValue'>
<div class="content_para"><p>Measure was not adapted from another source.</p></div>
</div>

</div>
<div class='field field_date'>
<h3>
Release Date
</h3>
<div class='FieldValue'>
1997 Sep
</div>

</div>
<div class='field field_text'>
<h3>
Measure Status
</h3>
<div class='FieldValue'>
<div class="content_para"><p>This is the current release of the measure.</p></div>
</div>

</div>
<div class='field field_citation'>
<h3>
Source(s)
</h3>
<div class='FieldValue'>
<table><tr><td>Young AS, Sullivan G, Burnam MA, Brook RH. Measuring the quality of outpatient treatment for schizophrenia. Arch Gen Psychiatry. 1998 Jul;55(7):611-7. <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=9672051" target="_blank">PubMed</a></td></tr></table>
</div>

</div>
<div class='field field_text'>
<h3>
Measure Availability
</h3>
<div class='FieldValue'>
<div class="content_para"><p>The individual measure, "Poor Quality Medication Treatment: the Appropriateness of Medication Management," is published in "Measuring the Quality of Outpatient Treatment for Schizophrenia."</p>

<p>For further information, contact: Alexander Young, M.D., M.S.H.S.,
West Los Angeles VA Healthcare Center, VISN 22 MIRECC, 11301 Wilshire Blvd. (210A), Los Angeles, CA 90073; Phone: 310-268-3647.</p></div>
</div>

</div>
<div class='field field_text'>
<h3>
NQMC Status
</h3>
<div class='FieldValue'>
<div class="content_para"><p>This NQMC summary was completed by ECRI on June 6, 2003.  The information was verified by the measure developer on July 11, 2003.</p></div>
</div>

</div>
<div class='field field_text'>
<h3>
Copyright Statement
</h3>
<div class='FieldValue'>
<div class="content_para"><p>No copyright restrictions apply.</p></div>
</div>

</div>

</div>
<div class='section'>
<h2>Disclaimer
</h2>
<div class='field field_text'>
<h3>
NQMC Disclaimer
</h3>
<div class='FieldValue'>
<p>The National Quality Measures Clearinghouseâ„¢ (NQMC) does not develop, produce, approve, or endorse the measures represented on this site.</p> 
<p>All measures summarized by NQMC and hosted on our site are produced under the auspices of medical specialty societies, relevant professional associations, public and private organizations, other government agencies, health care organizations or plans, individuals, and similar entities.</p> 
<p>Measures represented on the NQMC Web site are submitted by measure developers, and are screened solely to determine that they meet the <a href="/help-and-about/summaries/inclusion-criteria">NQMC Inclusion Criteria</a>.</p> 
<p>NQMC, AHRQ, and its contractor ECRI Institute make no warranties concerning the content or its reliability and/or validity of the quality measures and related materials represented on this site. Moreover, the views and opinions of developers or authors of measures represented on this site do not necessarily state or reflect those of NQMC, AHRQ, or its contractor, ECRI Institute, and inclusion or hosting of measures in NQMC may not be used for advertising or commercial endorsement purposes.</p> 
<p>Readers with questions regarding measure content are directed to contact the measure developer.</p>
</div>

</div>

</div>
</body></html>